5:15 PM ET
10-Q
Financial Results
Keenova Therapeutics Q3 2026 Results: Net Loss of $96.1M, Loss Narrows
Keenova Therapeutics reported net sales of $549.5 million for the quarter ended September 30, 2026, a significant increase from $416.1 million in the prior year. Despite higher revenue, the company recorded a net loss of $96.1 million for the quarter and $430.1 million for the nine-month period, primarily driven by a $150.6 million loss on divestiture and $207.7 million in non-restructuring impairment charges.
- Key figure
- Net loss $96.1M